Market Overview

Ensysce Biosciences to Present Novel TAP Opioid Technology at 7th Annual Gateway Investor Conference September 5, 2018

Share:

The promise of protection from opioid abuse.

Ensysce Biosciences, Inc., an integrated drug delivery company for both
small and large molecules, today announced that D. Lynn Kirkpatrick,
Ph.D., Chief Executive Officer, will present at the upcoming 7th
Annual Gateway Conference, ‘Overcoming Drug Abuse, Misuse and Overdose'.
The Conference is being held September 5-6, 2018, at the Four Seasons,
San Francisco, California. Dr. Kirkpatrick will discuss the company's
TAP opioid abuse and overdose protection technologies that can help to
prevent the serious problems of drug misuse and overdose. Further
information on details on the Gateway Conference can be found here.

Dr. Kirkpatrick will highlight advances in Ensysce's Trypsin Activated
Prodrug (TAP) platform that delivers safer opioid analgesics with the
promise of true overdose protection. The opioid crisis in America is
growing and abuse deterrent formulations have proved ineffective in
curbing the epidemic. The goal of the TAP opioid platform is to provide
an effective and truly abuse proof alternative. TAP products are
activated in the digestive system, eliminating the ability to abuse and
misuse opioid, ADHD and other prescription drugs by chewing, inhalation
or manipulation and injection. Ensysce's lead product, PF614, an
extended release TAP oxycodone, has received Fast Track Status from the
FDA and is quickly moving through clinical development.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is an integrated drug delivery
company for both small and large molecules. To overcome the major
problem of non-medical use of opioid products, Ensysce is using its
prodrug technology to improve abuse deterrent properties. The TAP
BIO-MD™ abuse deterrent and MPAR™ overdose resistant pain platforms,
with worldwide intellectual patent protection, eliminate the ability to
abuse opioid products by the non-oral route. This abuse is the fastest
growing drug problem in the U.S. and it leads to billions in healthcare
costs annually. For additional information about Ensysce Biosciences
please visit www.ensysce.com.

View Comments and Join the Discussion!